Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844615 | 0.79 | MEN1 (0.40) | PIK3CD | |
| SCHEMBL13548275 | 0.79 | FGFR1 (0.34) | TLR8PIK3CD | |
| SCHEMBL10855532 | 0.75 | PARP1 (0.39) | CYP2A6PIK3CD | |
| SCHEMBL2846208 | 0.75 | RECQL (0.36) | PIK3CD | |
| SCHEMBL9564539 | 0.72 | HTR1B (0.46) | HRH1MAOATLR8CYP2A6 | |
| SCHEMBL4865405 | 0.71 | MAOA (0.48) | HRH1MAOA | |
| SCHEMBL30195937 | 0.71 | MAOA (0.48) | HRH1MAOA | |
| SCHEMBL13547873 | 0.71 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL3527310 | 0.70 | MAOA (0.47) | HRH1MAOA | |
| SCHEMBL10559790 | 0.69 | HRH3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | HRH1 578/4885MAOA 265/4885TLR8 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.